Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75

Jade Biosciences, Inc. (NASDAQ:JBIO) has earned an average recommendation of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $51.75.

A number of research analysts recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 price target on shares of Jade Biosciences in a research note on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Jade Biosciences in a report on Friday, September 11th. BTIG Research boosted their price objective on Jade Biosciences from $74.00 to $77.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Jade Biosciences in a research note on Thursday, October 1st. Finally, Wedbush reissued an “outperform” rating and set a $47.00 target price on shares of Jade Biosciences in a report on Thursday, October 1st.

Jade Biosciences Stock Down 0.6%

JBIO opened at $14.50 on Tuesday. Jade Biosciences has a 52-week low of $8.36 and a 52-week high of $28.00. The firm’s fifty day simple moving average is $17.36 and its two-hundred day simple moving average is $18.11.

Jade Biosciences (NASDAQ:JBIO) last announced its earnings results on Monday, August 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Equities research analysts expect that Jade Biosciences will post -2.89 EPS for the current year.

Institutional Trading of Jade Biosciences

Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new position in Jade Biosciences in the 2nd quarter valued at $1,896,000. Janus Henderson Group PLC acquired a new stake in Jade Biosciences during the 1st quarter worth $43,557,000. Renaissance Technologies LLC grew its holdings in shares of Jade Biosciences by 94.0% during the first quarter. Renaissance Technologies LLC now owns 135,039 shares of the company’s stock worth $1,897,000 after buying an additional 65,438 shares in the last quarter. Stempoint Capital LP purchased a new stake in shares of Jade Biosciences during the first quarter worth $2,164,000. Finally, Maven Securities LTD purchased a new stake in shares of Jade Biosciences during the second quarter worth $1,111,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for autoimmune and other immune-mediated diseases. The company is building a pipeline of antibody-based therapies designed to modulate the immune system and address significant unmet medical needs.

Jade’s development programs include JDB001, an investigational therapeutic being advanced for potential use in immune-mediated conditions. The company’s product candidates remain in clinical development and have not been approved for commercial use.

Jade Biosciences is headquartered in the United States and conducts its research and development activities through a biotechnology-focused operating model.